Mineralys Therapeutics, Inc.

MLYS

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Dec 15, 2025

Drug Pipeline

Drug Name	Phase	Indication	Designations
lorundrostat Dose 1	Phase 3	Hypertension	-
Lorundrostat	Phase 2	Obstructive Sleep Apnea	-
Placebo	Phase 2	Hypertension	-
MLS-101 (Part I)	Phase 2	Hypertension, Renal	-
Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD	Phase 2	Chronic Kidney Disease	-

Catalyst Timeline

3 upcoming, 0 past

Phase 2Next

December 2025~Lorundrostat

Primary completion for Lorundrostat trial (NCT06785454) in Obstructive Sleep Apnea

⭐Phase 3

December 2025~Placebo

Primary completion for Placebo trial (NCT05968430) in Hypertension